Dupilumab-induced Urticaria

Affiliations

¹ Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
² Allergy and Clinical Immunology Unit, Department of Medical Sciences, University of Turin and Mauriziano Hospital, Turin, Italy.

Luca Mastorino et al. Dermatol Ther. 2021 Nov.

. 2021 Nov;34(6):e15117.

doi: 10.1111/dth.15117. Epub 2021 Sep 6.

¹ Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
² Allergy and Clinical Immunology Unit, Department of Medical Sciences, University of Turin and Mauriziano Hospital, Turin, Italy.

No abstract available

References

1. Shirley M. Dupilumab: first global approval. Drugs. 2017;77:1115-1121.
1. Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3 suppl 1):S28-S36. https://doi.org/10.1016/j.jaad.2017.12.022
1. Thaçi DL, Simpson E, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94(2):266-275. https://doi.org/10.1016/j.jdermsci.2019.02.002
1. Soria A, Du-Thanh A, Seneschal J, et al. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with Dupilumab. JAMA Dermatol. 2019;155(11):1312-1315. https://doi.org/10.1001/jamadermatol.2019.2613
1. Al-Janabi A, Marsland AM. Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: two case reports. Clin Case Rep. 2020;8(8):1458-1460. https://doi.org/10.1002/ccr3.2871